"Viral Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.
Descriptor ID |
D014765
|
MeSH Number(s) |
D20.215.894.899
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Viral Vaccines".
Below are MeSH descriptors whose meaning is more specific than "Viral Vaccines".
This graph shows the total number of publications written about "Viral Vaccines" by people in this website by year, and whether "Viral Vaccines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 |
1995 | 2 | 1 | 3 |
1996 | 4 | 1 | 5 |
1997 | 1 | 1 | 2 |
1998 | 6 | 1 | 7 |
1999 | 2 | 1 | 3 |
2000 | 6 | 1 | 7 |
2001 | 4 | 1 | 5 |
2002 | 5 | 2 | 7 |
2003 | 10 | 0 | 10 |
2004 | 6 | 5 | 11 |
2005 | 4 | 8 | 12 |
2006 | 8 | 1 | 9 |
2007 | 2 | 1 | 3 |
2008 | 2 | 0 | 2 |
2009 | 3 | 4 | 7 |
2010 | 2 | 1 | 3 |
2011 | 2 | 1 | 3 |
2012 | 3 | 2 | 5 |
2013 | 1 | 0 | 1 |
2014 | 4 | 1 | 5 |
2015 | 3 | 2 | 5 |
2016 | 4 | 3 | 7 |
2017 | 5 | 1 | 6 |
2018 | 1 | 3 | 4 |
2019 | 4 | 2 | 6 |
2020 | 14 | 3 | 17 |
2021 | 4 | 2 | 6 |
2022 | 9 | 1 | 10 |
2023 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Viral Vaccines" by people in Profiles.
-
Safety and Immunogenicity of Live Viral Vaccines in a Multicenter Cohort of Pediatric Transplant Recipients. JAMA Netw Open. 2023 10 02; 6(10):e2337602.
-
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer. Int J Gynecol Cancer. 2023 09 04; 33(9):1458-1463.
-
Epitope-based vaccine design against the membrane and nucleocapsid proteins of SARS-CoV-2. Dent Med Probl. 2023 Jul-Sep; 60(3):489-495.
-
Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021. Vaccine. 2023 08 23; 41(37):5424-5434.
-
In silico formulation of a next-generation multiepitope vaccine for use as a prophylactic candidate against Crimean-Congo hemorrhagic fever. BMC Med. 2023 02 01; 21(1):36.
-
Longitudinal Analysis of the Phenotype, Transcriptional Profile, and Anatomic Location of Memory CD8 T Cell Subsets after Acute Viral Infection. J Virol. 2023 01 31; 97(1):e0155622.
-
A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2. Emerg Microbes Infect. 2022 Dec; 11(1):2724-2734.
-
High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster. J Infect Dis. 2022 10 17; 226(8):1401-1406.
-
A bivalent SARS-CoV-2 monoclonal antibody combination does not affect the immunogenicity of a vector-based COVID-19 vaccine in macaques. Sci Transl Med. 2022 10 05; 14(665):eabo6160.
-
Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide cohort study comparing three COVID-19 vaccination protocols in South Korea. Front Immunol. 2022; 13:968105.